Tobias Grabe, Dr. rer. nat.

Position: Postdoctoral Fellow

Room no.: CP-02-110

Telephone no.: +49 231 755 7053

Member of the group since: 05/2016

University Degree: Dr. rer. nat., Medicinal Chemistry and Chemical Biology, TU Dortmund University


Expertise: organic synthesis, structure-based design

Off-Lab activities (hobbies): music, concerts, playing guitar, football

Research project:

The development of ErbB receptor tyrosine kinase inhibitors brought a powerful tool to clinicians for the treatment of several types of cancer. However, resistance mutations occur, leaving the therapeutic agent ineffective. Therefore, the development of novel inhibitors for the treatment of clinically relevant mutations is a major challenge in modern cancer drug discovery.


Earlier positions:

  • Bachelor studies at the TU Dortmund in the group of Prof. Arno Behr on the development of water-soluble catalyst-systems for green, homogeneous catalysis;
  • 3 years as student worker in the group of Dr. Andreas Vorholt
  • Master studies at Rauh group on design and synthesis of inhibitors of the ErbB-family



  1. Lategahn, J.; Hardick, J.; Grabe, T.; Niggenaber, J.; Jeyakumar, K.; Keul, M.; Tumbrink, H. L.; Becker, C.; Hodson, L.; Kirschner, T.; Klövekorn, P.; Ketzer, J.; Baumann, M.; Terheyden, S.; Unger, A.; Weisner, J.; Müller, M. P.; van Otterlo, W. A. L.; Bauer, S.; Rauh, D.. Targeting Her2-insYVMA with Covalent Inhibitors-A Focused Compound Screening and Structure-Based Design Approach. J. Med. Chem. 2020, 63 (20), 11725–11755.

    DOI PubMed

  2. Lategahn, J.; Keul, M.; Klövekorn, P.; Tumbrink, H. L.; Niggenaber, J.; Müller, M. P.; Hodson, L.; Flaßhoff, M.; Hardick, J.; Grabe, T.; Engel, J.; Schultz-Fademrecht, C.; Baumann, M.; Ketzer, J.; Mühlenberg, T.; Hiller, W.; Günther, G.; Unger, A.; Müller, H.; Heimsoeth, A.; Golz, C.; Blank-Landeshammer, B.; Kollipara, L.; Zahedi, R. P.; Strohmann, C.; Hengstler, J. G.; van Otterlo, W. A. L.; Bauer, S.; Rauh, D.. Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797S. Chem. Sci. 2019, 10 (46), 10789–10801.

    DOI PubMed

  3. Grabe, T.; Lategahn, J.; Rauh, D.. C797S Resistance: The Undruggable EGFR Mutation in Non-Small Cell Lung Cancer?. ACS Med. Chem. Lett. 2018, 9 (8), 779–782.

    DOI PubMed